Autolus Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview

Autolus Therapeutics

01/03/2024 07:03

* Autolus Therapeutics PLC  AUTL.OQ   AUTL.O  is expected
to show
a fall in quarterly revenue when it reports  results on March 14
for the period ending December 31 2023
    * The London United Kingdom-based   company is expected to
report
a 90.6% decrease in revenue to $358.4 thousand from $3.83
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Autolus Therapeutics PLC
is
for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Autolus
Therapeutics PLC is $10.00​, above​ its last closing price
of $6.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.26       -0.25      -0.26     Missed  -4
 Jun. 30 2023  -0.21       -0.22      -0.26     Missed  -15.9
 Mar. 31 2023  -0.26       -0.27      -0.23     Beat    13.6​
 Dec. 31 2022  -0.06       -0.27      -0.23     Beat    14.4
 ​​Sep.        -0.49       -0.46      -0.47     Missed  -1
 30 2022                                                
 Jun. 30 2022  -0.42       -0.42      -0.46     Missed  -9.5​
 Mar. 31 2022  -0.49       -0.48      -0.41     Beat    14.8
 Dec. 31 2021  -0.53       -0.46      -0.51     Missed  -10.5
 This summary was machine generated March 1 at 07:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)